Concepedia
Statistics
Publications
196
Citations
20.5K
H-Index
73
Active since
1992
Affiliations
Johns Hopkins University(Current)
Sidney Kimmel Comprehensive Cancer Center
University of Pennsylvania
The University of Texas MD Anderson Cancer Center
Johns Hopkins Medicine
Mark J. Levis is an author at Johns Hopkins University specializing in medicine, oncology, and hematology.
Top concepts
MedicineOncologyHematologyCancer ResearchHealthRadiation OncologyImmunologyPharmacotherapyPathologyPharmacology
Publications per year
1992–2025
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 734 citations
Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 630 citations · Full text
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
B. Douglas Smith, Mark J. Levis, Miloslav Beran et al. · Blood · 2004 · 622 citations
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng, Yue Shi, Ismael Samudio et al. · Blood · 2008 · 509 citations · Full text
Rows per page
1–5 of 196